

DAFTAR PUSTAKA

1. Kementerian Kesehatan Republik Indonesia. **Survei Kesehatan Indonesia (SKI) Tahun 2023**. Jakarta: Kemenkes RI; 2023.
2. World Health Organization. **Global Adult Tobacco Survey (GATS): Indonesia Report 2021**. Geneva: WHO; 2021.
3. Miller MR, Hankinson J, Brusasco V, et al. **Standardisation of spirometry**. Eur Respir J. 2005;26(2):319–338.
4. Pellegrino R, Viegi G, Brusasco V, et al. **Interpretative strategies for lung function tests**. Eur Respir J. 2005;26(5):948–968.
5. Graham BL, Steenbruggen I, Miller MR, et al. **Standardization of Spirometry 2019 Update**. Am J Respir Crit Care Med. 2019;200(8):e70–e88.
6. Akhter S, Ali MA, Rahman MA, et al. **Effect of smoking on FEF25–75 and other spirometric parameters**. Bangladesh Med Res Counc Bull. 2014;40(1):1–5.
7. McKenzie DK, Elliott M. **Small airway disease: clinical implications**. Respirology. 2016;21(2):263–270.
8. Peraturan Menteri Kesehatan Republik Indonesia Nomor 28 Tahun 2013 tentang **Pencantuman Peringatan Kesehatan dan Informasi Kesehatan pada Kemasan Produk Tembakau**.
9. American Thoracic Society. **Pulmonary Function Testing Guidelines**. Am J Respir Crit Care Med. 2017.
10. Quanjer PH, Stanojevic S, Cole TJ, et al. **Multi-ethnic reference values for spirometry**. Eur Respir J. 2012;40(6):1324–1343.
11. Lueallen EC, Fowler WS. **Maximum mid-expiratory flow**. Am Rev Tuberc. 1955;72:783–800.
12. Miller MR, Crapo R, Hankinson J, et al. **General considerations for lung function testing**. Eur Respir J. 2005;26:153–161.
13. Mead J. **The lung's “quiet zone”**. N Engl J Med. 1970;282:1318–1319.
14. Hyatt RE, Scanlon PD, Nakamura M. **Interpretation of Pulmonary Function Tests**. 4th ed. Philadelphia: Wolters Kluwer; 2014.
15. Barnes PJ. **Inflammatory mechanisms in patients with chronic obstructive pulmonary disease**. J Allergy Clin Immunol. 2016;138(1):16–27.
16. Global Initiative for Chronic Obstructive Lung Disease (GOLD). **Global Strategy for the Diagnosis, Management, and Prevention of COPD 2025 Report**.

17. West JB. **Respiratory Physiology: The Essentials**. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2016.
18. Bhatt SP, et al. **Small airway disease and COPD progression**. *Lancet Respir Med*. 2023;11(3):241–253.
19. U.S. Department of Health and Human Services. **The Health Consequences of Smoking—50 Years of Progress**. 2014.
20. Rahman I, Adcock IM. **Oxidative stress and redox regulation of lung inflammation in COPD**. *Eur Respir J*. 2006;28(1):219–242.
21. Hiemstra PS, McCray PB, Bals R. **The innate immune function of airway epithelial cells**. *Eur Respir J*. 2015;45(4):1150–1162.
22. Barnes PJ. **Cellular and molecular mechanisms of COPD**. *Clin Chest Med*. 2014;35(1):71–86.
23. Fletcher C, Peto R. **The natural history of chronic airflow obstruction**. *BMJ*. 1977;1:1645–1648.
24. Gelb AF, Zamel N. **Unsuspected pseudorestriction and hyperinflation in COPD**. *Chest*. 2000;117:42–47.
25. Anand Kumar P, et al. **Pulmonary function changes in smokers**. *Indian J Physiol Pharmacol*. 2012;56(3):257–262.
26. Aditama TY. **Rokok dan kesehatan paru**. Jakarta: UI Press; 2011.
27. Ernst A, Zibrak JD. **Carbon monoxide poisoning**. *N Engl J Med*. 1998;339:1603–1608.
28. Middleton ET, Morice AH. **Breath carbon monoxide as an indication of smoking habit**. *Chest*. 2000;117:758–763.
29. Ryter SW, Choi AMK. **Carbon monoxide in exhaled breath**. *Am J Respir Crit Care Med*. 2013;188(7):743–749.
30. Li X, et al. **Association of exhaled carbon monoxide with lung function in smokers**. *BMC Pulm Med*. 2020;20:216.
31. Jayasuriya NA, et al. **Exhaled CO and spirometric indices in smokers**. *Respirology*. 2019;24(5):463–470.
32. Saha A, et al. **Effect of smoking on FEV1/FVC and FEF25–75**. *J Clin Diagn Res*. 2017;11(4):CC04–CC07.